Erratum

This article refers to:

Synthesis and Characterization of Potential Impurities of the Antimigraine Drug, Rizatriptan Benzoate

In the article, “Synthesis and Characterization of Potential Impurities of the Antimigraine Drug, Rizatriptan Benzoate” by P. S. Sarma et al., published in Synthetic Communications, 38(4), p. 603–612, the following figure and schemes were to be included in the text:

Figure 1 Rizatriptan benzoate.

Scheme 1 Synthesis of Rizatriptan benzoate (1)

Scheme 2 Synthesis of 1-(4-(2-(4-(Dimethylamino) butylidene) -hydrazino) phenyl) -methyl -1,2,4 triazole (6).

Scheme 3 Synthesis of Rizatriptan N-Oxide impurity (7).

Scheme 4 Synthesis of Rizatriptan dimer impurity (9).

Scheme 5 Synthesis of Desmethyl rizatriptan (15).

Scheme 6 Synthesis of 5-(1H-1, 2,4-triazol-1yl-methyl)-1H-indole -3-ethanamine hydrochloride (14).

Scheme 7 Synthesis of N-methyl rizatriptan (15).

Notes

¹To whom correspondence should be addressed. Fax: [phone]; Ph. No: [phone]; E-mail: [email protected]